Molecular biology

Global Molecular Cytogenetics Market Research Report 2023: Rising Adoption of Array Based CGH to Spur Overall Demand - Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 26, 2023

The "Molecular Cytogenetics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Molecular Cytogenetics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
  • This market encompasses various facets, including Molecular Cytogenetics itself, Consumables, Instruments, Software & Services, as well as techniques like CGH (Comparative Genomic Hybridization), FISH (Fluorescence In Situ Hybridization), Immunohistochemistry, Karyotyping, and other methods.
  • The U.S. market, with an estimated worth of US$794.6 million in 2022, holds a prominent position within this market.
  • This report provides an extensive analysis of the global Molecular Cytogenetics market, furnishing insights into annual revenues, historical patterns, and future forecasts spanning from 2014 to 2030.

Moolec Science Presents Fourth Quarter FY 2023 Business Update

Retrieved on: 
Saturday, October 21, 2023

Luxembourg, Oct 21, 2023 - (ACN Newswire) - Moolec Science SA (NASDAQ:MLEC) a science-based food ingredient company focused on producing animal proteins in plants through Molecular Farming, today reported its Business Update for the fourth quarter of Fiscal Year 2023 ended June 30, 2023.

Key Points: 
  • Luxembourg, Oct 21, 2023 - (ACN Newswire) - Moolec Science SA (NASDAQ:MLEC) a science-based food ingredient company focused on producing animal proteins in plants through Molecular Farming, today reported its Business Update for the fourth quarter of Fiscal Year 2023 ended June 30, 2023.
  • The main highlights of the Company's business update are as follows:
    - Piggy Sooy(TM): introducing a soybean platform that can produce high amounts of pork protein.
  • These commitments will drive Moolec's business model forward through additional liquidity and enhanced capabilities," said Jose Lopez Lecube, Chief Financial Officer and Director of Moolec Science.
  • For a full version of Moolec's fourth quarter Fiscal Year 2023 Business Update, click here.

TransCode Therapeutics Announces Preliminary Clinical Results in First Patient in Phase 0 Clinical Study with Lead Therapeutic Candidate, TTX-MC138

Retrieved on: 
Tuesday, October 24, 2023

In addition, radiolabeled TTX-MC138 had pharmacokinetic behavior consistent with that expected based on non-clinical IND-enabling studies.

Key Points: 
  • In addition, radiolabeled TTX-MC138 had pharmacokinetic behavior consistent with that expected based on non-clinical IND-enabling studies.
  • Complete analysis of data from this first patient is in process and will be included in the final report for all patients enrolled in the study.
  • The trial is intended to yield important data regarding TTX-MC138 delivery to clinical metastases that could inform dose selection and frequency, for further clinical development.
  • “Our Phase 0 trial involves a single microdose of radiolabeled TTX-MC138 followed by noninvasive PET-MRI imaging and metabolite analysis.

HOW VETERANS ARE TRANSITIONING FROM THE FRONT LINES TO BECOME BUSINESS OWNERS

Retrieved on: 
Tuesday, October 24, 2023

TYSONS, Va., Oct. 24, 2023 /PRNewswire/ --

Key Points: 
  • While almost 50% of veterans returning home from World War II started businesses, that number is down to 4.5% today.
  • The biggest challenge faced by today's veterans is access to the funds and social networks needed to start and grow their businesses.
  • That's why the PenFed Foundation launched the Veteran Entrepreneur Investment Program (VEIP), which equips military members and veterans with the resources and training needed to realize their business aspirations.
  • She's been named to the HillVets 100, an honor designated for the country's most influential veterans, service members and advocates.

Immunome Appoints Bob Lechleider, M.D., as Chief Medical Officer

Retrieved on: 
Thursday, October 19, 2023

Immunome , Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Bob Lechleider, M.D., as Chief Medical Officer.

Key Points: 
  • Immunome , Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Bob Lechleider, M.D., as Chief Medical Officer.
  • Dr. Lechleider brings over 20 years of experience as an academic and industry executive in medical oncology and cancer research.
  • “We are delighted to welcome Bob to our team during an exciting time in Immunome’s growth as we focus on advancing our oncology pipeline into the clinic,” said Dr. Siegall, President and Chief Executive Officer of Immunome.
  • I would like to extend my thanks to Dr. Siegall and the entire Immunome team for welcoming me to the company,” said Bob Lechleider, M.D., Chief Medical Officer of Immunome.

Nucleix Bladder EpiCheck® Now Available in France via the Association Francaise d'Urologie (AFU) Registry for Surveillance of Recurrence of Bladder Cancer

Retrieved on: 
Monday, October 23, 2023

Nucleix , a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced participation in the Association Francaise d'Urologie (AFU) Registry of the Therapeutic Management and Follow-Up of Non-Muscle-Invasive Bladder Cancer (TVNIM-AFU).

Key Points: 
  • Nucleix , a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced participation in the Association Francaise d'Urologie (AFU) Registry of the Therapeutic Management and Follow-Up of Non-Muscle-Invasive Bladder Cancer (TVNIM-AFU).
  • The registry will evaluate the diagnostic performance of selected urine biomarkers in French patients and compare them to the results of bladder endoscopies (cystoscopy) performed over two years for routine follow-up of NMIBC.
  • The registry is open to all urologists who are members of the AFU to include patients undergoing tumor resection.
  • Bladder EpiCheck testing will be performed by Inovie Gen-Bio, a network that conducts molecular biology and genetic testing across France.

Mays Cancer Center: Targeting certain molecular interactions could yield new strategies for treating prostate cancer

Retrieved on: 
Friday, October 20, 2023

SAN ANTONIO, Oct. 20, 2023 /PRNewswire-PRWeb/ -- Research led by Mays Cancer Center at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has discovered that altering certain molecular interactions could yield new strategies for treating prostate cancer and related diseases.

Key Points: 
  • SAN ANTONIO, Oct. 20, 2023 /PRNewswire-PRWeb/ -- Research led by Mays Cancer Center at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has discovered that altering certain molecular interactions could yield new strategies for treating prostate cancer and related diseases.
  • "Our results provide molecular insights for potential therapeutic strategies to treat prostate cancer and other AR-involved diseases by targeting AR multivalent interactions," said Zhijie "Jason" Liu, PhD, associate professor and CPRIT Scholar in Cancer Research with Mays Cancer Center and the Institute of Biotechnology of the Department of Molecular Medicine at UT Health San Antonio.
  • The Mays Cancer Center at UT Health San Antonio is one of only four National Cancer Institute-designated Cancer Centers in Texas.
  • The Mays Cancer Center provides leading-edge cancer care, propels innovative cancer research and educates the next generation of leaders to end cancer in South Texas.

Genascence Names Ian Lachlan McLean, M.D. Ph.D. as Chief Medical Officer

Retrieved on: 
Wednesday, October 18, 2023

PALO ALTO, Calif., Oct. 18, 2023 /PRNewswire/ -- Genascence Corporation ("Genascence"), a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy, today announced the appointment of Ian Lachlan (Lachy) McLean, M.D., Ph.D. as its chief medical officer. Dr. McLean brings extensive leadership experience in both early and late-stage clinical research and development (R&D) in the biopharmaceutical space, as well as complimentary clinical practice expertise as a rheumatologist to Genascence. He will lead Genascence's clinical development strategy.

Key Points: 
  • —Seasoned physician-scientist and R&D executive, with significant experience building and growing successful clinical development organizations—
    PALO ALTO, Calif., Oct. 18, 2023 /PRNewswire/ -- Genascence Corporation ("Genascence"), a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy, today announced the appointment of Ian Lachlan (Lachy) McLean, M.D., Ph.D. as its chief medical officer.
  • "On behalf of the entire Genascence organization and board of directors, I am thrilled to welcome Lachy as our chief medical officer," said Thomas Chalberg, Ph.D., founder and CEO of Genascence.
  • "Genascence is at the forefront of transforming how we treat prevalent and debilitating musculoskeletal diseases like osteoarthritis with gene therapy," said Dr. McLean.
  • Before joining Genascence, Dr. McLean was chief medical officer at Novome, a start-up biotech company developing engineered bacteria as a drug-delivery platform.

Vilya Appoints Cyrus Harmon, Ph.D., as Chief Executive Officer

Retrieved on: 
Tuesday, October 17, 2023

VILYA, Inc. (Vilya), a biotechnology company creating a new class of medicines that precisely target disease biology, today announced the appointment of Cyrus Harmon, Ph.D., as its Chief Executive Officer.

Key Points: 
  • VILYA, Inc. (Vilya), a biotechnology company creating a new class of medicines that precisely target disease biology, today announced the appointment of Cyrus Harmon, Ph.D., as its Chief Executive Officer.
  • “I am very excited to join the phenomenal team at Vilya developing new macrocycle drugs,” said Harmon.
  • Previously, Harmon co-founded and served as CEO of Olema Oncology, a company focused on women’s cancers, before transitioning to the role of Chief Research Officer.
  • Harmon joins Katerina Leftheris, Ph.D., Vilya’s Chief Scientific Officer on the company’s leadership team.

Phoenix Children's Expands Research Team with Scientist Pioneering New Childhood Cancer Treatments

Retrieved on: 
Tuesday, October 17, 2023

PHOENIX, Oct. 17, 2023 /PRNewswire/ -- Phoenix Children's, one of the nation's fastest-growing pediatric health systems, continues to strengthen its focus on pediatric research with the hire of Tanya Kalin, MD, PhD, a renowned scientist focused on pioneering effective treatments for pediatric cancers with fewer negative side effects for children. Dr. Kalin also serves as vice chair of translational research for the Phoenix Children's Center for Cancer and Blood Disorders, and as a professor of Child Health at the University of Arizona College of Medicine – Phoenix.

Key Points: 
  • Dr. Kalin also serves as vice chair of translational research for the Phoenix Children's Center for Cancer and Blood Disorders , and as a professor of Child Health at the University of Arizona College of Medicine – Phoenix.
  • Dr. Kalin, who assumed her new post in recent weeks, comes to Phoenix Children's from Cincinnati Children's, where she founded and directed her namesake Kalin Research Lab.
  • Two members of her lab also are moving to Phoenix Children's to continue their research with Dr. Kalin.
  • Research underway at Phoenix Children's consists of more than 700 active studies, 640 research investigators and 90 research staff members including research scientists, associates, biostatisticians, pharmacists, nurses, coordinators and assistants.